

Sebastian Havervall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9606528/publications.pdf>

Version: 2024-02-01

24
papers

1,238
citations

687363

13
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

2398
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2015.	7.4	286
2	SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. <i>Nature Communications</i> , 2020, 11, 5064.	12.8	243
3	Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 878-882.	2.4	157
4	Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 988-994.	2.4	146
5	Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers. <i>Journal of Medical Virology</i> , 2021, 93, 5908-5916.	5.0	50
6	Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. <i>Journal of Internal Medicine</i> , 2022, 291, 72-80.	6.0	47
7	Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. <i>EBioMedicine</i> , 2021, 70, 103523.	6.1	42
8	Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. <i>EMBO Molecular Medicine</i> , 2022, 14, .	6.9	35
9	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3695.	12.8	32
10	SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. <i>PLoS ONE</i> , 2022, 17, e0262169.	2.5	29
11	Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. <i>Clinical and Translational Immunology</i> , 2021, 10, e1312.	3.8	24
12	Neutrophil extracellular traps in patients with liver cirrhosis and hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 18025.	3.3	20
13	Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. <i>Clinical and Translational Immunology</i> , 2022, 11, e1388.	3.8	20
14	COVID-19 is Associated with an Acquired Factor XIII Deficiency. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1668-1669.	3.4	15
15	Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. <i>Vaccines</i> , 2022, 10, 359.	4.4	11
16	An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. <i>PLoS ONE</i> , 2021, 16, e0258041.	2.5	10
17	Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 267-269.	3.8	10
18	An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism. <i>Scientific Reports</i> , 2021, 11, 14015.	3.3	8

#	ARTICLE	IF	CITATIONS
19	A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 795026.	3.9	8
20	Response by Mackman et al to Letter Regarding Article, "Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality" Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e381-e382.	2.4	7
21	Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality. <i>American Journal of Hematology</i> , 2021, 96, E98-E100.	4.1	6
22	Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e595.	2.7	6
23	A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. <i>New Biotechnology</i> , 2022, 66, 46-52.	4.4	5
24	MO132 IMPACT OF MONOCYTE CHEMOATTRACTANTS ON IN-HOSPITAL MORTALITY IN RELATION TO KIDNEY FUNCTION IN PATIENTS WITH COVID-19. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0